Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oryzon Genomics SA ( (ES:ORY) ) has issued an update.
Oryzon Genomics SA has outlined its directors’ remuneration policy for the years 2023 to 2025, following approval by the General Shareholders’ Meeting. The policy emphasizes fixed remuneration without variable components, ensuring alignment with market standards and promoting effective risk management. This structured approach aims to maintain the independence of directors’ judgment and support the company’s long-term sustainability.
More about Oryzon Genomics SA
Oryzon Genomics SA is a company operating in the genomics industry, focusing on the development and commercialization of innovative therapeutic solutions. The company is engaged in the research and development of epigenetic drugs, which target specific gene expressions to treat various diseases, including cancer and neurodegenerative disorders.
YTD Price Performance: 90.67%
Average Trading Volume: 904
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €192.5M
For a thorough assessment of ORY stock, go to TipRanks’ Stock Analysis page.